secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapForce Inc. (CFOR)
CIK:        0001293818
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001079973-23-001602
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OpGen Q3 revenue $0.7M; subsidiaries Curetis & Ares Genetics file insolvency, going concern doubt
--------------------------------------------------------------------------------

- Total revenue Q3 2023 $0.70M vs $0.45M; nine-month $2.35M vs $1.89M.
- Cash and equivalents $0.29M at Sep 30; subsequent financing raised ~$3.06M but substantial doubt about going concern.
- Subsidiaries Curetis GmbH and Ares Genetics GmbH filed for insolvency Nov 6, 2023 under German/Austrian laws.
- OpGen reduced U.S. headcount from 23 to 6; discontinued Acuitas AMR Gene Panel test.
- Total operating expenses Q3 2023 $4.26M vs $13.96M (incl. $6.98M goodwill impairment in prior year).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293818/000107997323001602/0001079973-23-001602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293818/000107997323001602/opgen_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-23-001602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer